Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567562 · ClinicalTrials.gov registry record · Phase 2
Anti-Platelets in Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05567562 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 15 participants.
The verdict
NCT05567562, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.
Interventions
- DRUG Placebo
- COMBINATION_PRODUCT dual anti-platelet therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2025-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05567562
The ClinicalTrials.gov registry entry for NCT05567562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05567562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05567562 about?
NCT05567562 is a clinical study titled "Anti-Platelets in Chronic Obstructive Pulmonary Disease". This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.
What is the current status of trial NCT05567562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2024-03-27. Estimated completion is 2025-02-28.
What interventions are being tested in trial NCT05567562?
The interventions under investigation include: Placebo (DRUG), dual anti-platelet therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05567562?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.